Case Report: Immune dysregulation in proteasome-associated autoinflammatory syndromes: insights from a clinical case study

Background Proteasome-associated autoinflammatory syndrome (PRAAS) is a genetically defined rare immune-dysregulatory disorder associated with impaired proteasome degradation. It is characterized by the type I interferon (IFN) signaling activation and variable systemic inflammation. Case presentation We report a patient with a clinical phenotype consistent with PRAAS who showed short-term clinical and immunological improvement following tofacitinib treatment. The patient presented with recurrent fever, rash, splenomegaly, leukopenia, elevated inflammatory cytokines, and dysregulated lymphocyte subsets, characterized by increased pro-inflammatory T helper (Th)1 and Th17 cells together with reduced frequency and impaired suppressive function of regulatory T cells (Tregs). Trio whole-exome sequencing identified compound heterozygous PSMB8 variants, c.-4118C>T and c.350T>C (p.Met117Thr), inherited from the father and mother, respectively; both variants were classified as variants of uncertain significance. Following treatment with the Janus kinase (JAK) inhibitor tofacitinib, the patient showed improvement in clinical manifestations, inflammatory parameters, and T-cell abnormalities. The integrated clinical, immunological, and genetic findings were considered consistent with a PRAAS phenotype. Conclusions This case highlights the value of comprehensive genetic and immunological evaluation in patients with suspected autoinflammatory disorders and illustrates marked T-cell immune dysregulation in a PRAAS-consistent phenotype. Tofacitinib treatment was associated with short-term clinical and immunological improvement in this patient; however, its long-term therapeutic efficacy requires confirmation in additional patients with longer follow-up.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1975064
Primary Topic
Immunodeficiency and Autoimmune Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Immune dysregulation in proteasome-associated autoinflammatory syndromes: insights from a clinical case study

Yajing Zhao, Xin Liu, Zhen Yu, Juanjuan Song et al.
2 links
Frontiers in Immunology
Immunodeficiency and Autoimmune Disorders
article

Case Report: Immune dysregulation in proteasome-associated autoinflammatory syndromes: insights from a clinical case study

Yajing Zhao, Xin Liu, Zhen Yu, Juanjuan Song, Ao Xie, Yu Wang, Hu Zhou
article en

Abstract

Background Proteasome-associated autoinflammatory syndrome (PRAAS) is a genetically defined rare immune-dysregulatory disorder associated with impaired proteasome degradation. It is characterized by the type I interferon (IFN) signaling activation and variable systemic inflammation. Case presentation We report a patient with a clinical phenotype consistent with PRAAS who showed short-term clinical and immunological improvement following tofacitinib treatment. The patient presented with recurrent fever, rash, splenomegaly, leukopenia, elevated inflammatory cytokines, and dysregulated lymphocyte subsets, characterized by increased pro-inflammatory T helper (Th)1 and Th17 cells together with reduced frequency and impaired suppressive function of regulatory T cells (Tregs). Trio whole-exome sequencing identified compound heterozygous PSMB8 variants, c.-4118C>T and c.350T>C (p.Met117Thr), inherited from the father and mother, respectively; both variants were classified as variants of uncertain significance. Following treatment with the Janus kinase (JAK) inhibitor tofacitinib, the patient showed improvement in clinical manifestations, inflammatory parameters, and T-cell abnormalities. The integrated clinical, immunological, and genetic findings were considered consistent with a PRAAS phenotype. Conclusions This case highlights the value of comprehensive genetic and immunological evaluation in patients with suspected autoinflammatory disorders and illustrates marked T-cell immune dysregulation in a PRAAS-consistent phenotype. Tofacitinib treatment was associated with short-term clinical and immunological improvement in this patient; however, its long-term therapeutic efficacy requires confirmation in additional patients with longer follow-up.

Frontiers in ImmunologyVol. 17
Shandong University (CN), Zhengzhou University (CN), Henan Cancer Hospital (CN), Qilu Hospital of Shandong University (CN)
National Natural Science Foundation of China
Good health and well-being
Immunodeficiency and Autoimmune Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon